X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (16) 16
oncology (13) 13
aged (11) 11
female (11) 11
middle aged (11) 11
cancer (10) 10
care and treatment (10) 10
chemotherapy (10) 10
male (10) 10
clinical trials (7) 7
product development (7) 7
research (7) 7
thyroid cancer (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
hematology, oncology and palliative medicine (6) 6
survival (6) 6
adult (5) 5
aged, 80 and over (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carcinoma (5) 5
deoxycytidine - administration & dosage (5) 5
deoxycytidine - analogs & derivatives (5) 5
metastases (5) 5
metastasis (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
adenocarcinoma (4) 4
bevacizumab (4) 4
cancer therapies (4) 4
capecitabine (4) 4
disease-free survival (4) 4
gemcitabine (4) 4
kaplan-meier estimate (4) 4
medical research (4) 4
pancreatic cancer (4) 4
pancreatic neoplasms - drug therapy (4) 4
patients (4) 4
studies (4) 4
therapy (4) 4
adenocarcinoma - drug therapy (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - therapeutic use (3) 3
biomarkers (3) 3
colorectal cancer (3) 3
combination (3) 3
diarrhea (3) 3
double-blind (3) 3
drug therapy (3) 3
esophageal neoplasms - drug therapy (3) 3
fluorouracil - administration & dosage (3) 3
fluorouracil - analogs & derivatives (3) 3
health aspects (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
medicine & public health (3) 3
motivation (3) 3
mutation (3) 3
oncology, experimental (3) 3
pancreas (3) 3
prognosis (3) 3
proportional hazards models (3) 3
quality of life (3) 3
radioactive iodine (3) 3
surgery (3) 3
time factors (3) 3
united kingdom (3) 3
usage (3) 3
1st-line treatment (2) 2
adenocarcinoma - mortality (2) 2
analysis (2) 2
articles (2) 2
association guidelines (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cancer patients (2) 2
carcinoma, pancreatic ductal - drug therapy (2) 2
case-control studies (2) 2
chi-square distribution (2) 2
cisplatin (2) 2
clinical medicine (2) 2
clinical-trials (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - pathology (2) 2
colorectal-cancer (2) 2
comparative analysis (2) 2
dna mutational analysis (2) 2
dosage and administration (2) 2
drug administration schedule (2) 2
drug therapy, combination (2) 2
endocrinology & metabolism (2) 2
endothelial growth-factor (2) 2
follow-up studies (2) 2
gastric cancer (2) 2
gastric-cancer (2) 2
gastroesophageal junction (2) 2
genetic loci (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 481 - 489
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | CETUXIMAB | PROSPECTIVE MULTICENTER | ONCOLOGY | GASTRIC-CANCER | PROGNOSTIC-SIGNIFICANCE | CELL-LINES | METASTATIC COLORECTAL-CANCER | ESOPHAGEAL ADENOCARCINOMA | III TRIAL | Multivariate Analysis | Adenocarcinoma - pathology | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Molecular Targeted Therapy | Esophageal Neoplasms - pathology | Early Termination of Clinical Trials | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Stomach Neoplasms - enzymology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | United Kingdom | Stomach Neoplasms - drug therapy | Chi-Square Distribution | Adenocarcinoma - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Esophageal Neoplasms - enzymology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Care and treatment | Anthracyclines | Product development | Cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 749 - 759
Summary Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | COLON-CANCER | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | PROSPECTIVE MOLECULAR STRATIFICATION | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | COMBINATION | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Camptothecin - therapeutic use | Drug Administration Schedule | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | United Kingdom | Chi-Square Distribution | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Colorectal cancer | Index Medicus
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 03/2018, Volume 44, pp. S9 - S9
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 11/2017, Volume 43, Issue 11, pp. 2209 - 2209
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 829 - 840
Summary Background We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in... 
Hematology, Oncology and Palliative Medicine | COLONY-STIMULATING FACTOR | ONCOLOGY | DUCTAL ADENOCARCINOMA | IMMUNOTHERAPY | METAANALYSES | SUPPRESSOR-CELLS | RESISTANT PROSTATE-CANCER | T-CELLS | CHEMOTHERAPY | IPILIMUMAB | TUMOR-ANTIGEN | Cell Proliferation | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Pain - chemically induced | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Female | Neutropenia - chemically induced | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Fluorouracil - analogs & derivatives | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Pancreatic Ducts | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Telomerase - administration & dosage | Disease-Free Survival | Telomerase - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | T-Lymphocytes - immunology | Aged | Peptide Fragments - adverse effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Hospitals | Gemcitabine | Peptides | Pancreatic cancer | Vaccination | Product development | Vaccines | Metastasis | Telomerase | Cancer
Journal Article
Gut, ISSN 0017-5749, 06/2018, Volume 67, Issue Suppl 1, p. A155
IntroductionPancreatic adenocarcinoma (PDAC) has a very poor prognosis with most patients presenting with advanced incurable disease. Palliative chemotherapy... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 486 - 499
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 18, pp. 1674 - 1685
In this trial, low-dose radioiodine was as effective as high-dose radioiodine in patients with differentiated thyroid tumors, and recombinant human thyrotropin... 
MEDICINE, GENERAL & INTERNAL | I-131 | THERAPY | SURVEILLANCE | PROGNOSTIC-SIGNIFICANCE | PAPILLARY | RADIOACTIVE IODINE | CARCINOMA | SERUM THYROGLOBULIN | IODINE REMNANT ABLATION | CONSENSUS REPORT | Ablation Techniques - psychology | Follow-Up Studies | Humans | Middle Aged | Male | Iodine Radioisotopes - adverse effects | Young Adult | Thyroid Hormones - blood | Aged, 80 and over | Adult | Female | Thyrotropin Alfa - therapeutic use | Ablation Techniques - adverse effects | Thyroid Hormones - therapeutic use | Thyrotropin Alfa - adverse effects | Length of Stay | Radiotherapy Dosage | Thyroid Neoplasms - surgery | Treatment Outcome | Combined Modality Therapy | Thyroid Neoplasms - radiotherapy | Thyroidectomy | Hypothyroidism - etiology | Iodine Radioisotopes - administration & dosage | Thyroid Neoplasms - drug therapy | Adolescent | Quality of Life | Aged | Drugs | Dose-response relationship (Biochemistry) | Usage | Care and treatment | Patient outcomes | Radiofrequency ablation | Product/Service Evaluations | Thyroid cancer | Thyrotropin | Dosage and administration | Drug therapy, Combination | Drug therapy | Isotopes | Iodine | Medical research | Data processing | Thyroid gland | Hypothyroidism | Patients | Lymph nodes | Quality of life | Metastases | Thyroid-stimulating hormone | Surgery | Triiodothyronine | Cancer | Thyroid
Journal Article
by Dunlop, Malcolm G and Dobbins, Sara E and Farrington, Susan Mary and Jones, Angela M and Palles, Claire and Whiffin, Nicola and Tenesa, Albert and Spain, Sarah and Broderick, Peter and Ooi, Li-Yin and Domingo, Enric and Smillie, Claire and Henrion, Marc and Frampton, Matthew and Martin, Lynn and Grimes, Graeme and Gorman, Maggie and Semple, Colin and Ma, Yusanne P and Barclay, Ella and Prendergast, James and Cazier, Jean-Baptiste and Olver, Bianca and Penegar, Steven and Lubbe, Steven and Chander, Ian and Carvajal-Carmona, Luis G and Ballereau, Stephane and Lloyd, Amy and Vijayakrishnan, Jayaram and Zgaga, Lina and Rudan, Igor and Theodoratou, Evropi and Thomas, Huw and Maher, Eamonn and Evans, Gareth and Walker, Lisa and Halliday, Dorothy and Lucassen, Anneke and Paterson, Joan and Hodgson, Shirley and Homfray, Tessa and Side, Lucy and Izatt, Louise and Donaldson, Alan and Tomkins, Susan and Morrison, Patrick and Brewer, Carole and Henderson, Alex and Davidson, Rosemarie and Murday, Victoria and Cook, Jaqueline and Haites, Neva and Bishop, Timothy and Sheridan, Eamonn and Green, Andrew and Marks, Christopher and Carpenter, Sue and Broughton, Mary and Greenhalge, Lynn and Suri, Mohnish and Starr, John M and Deary, Ian and Kirac, Iva and Kovacevia, Dujo and Aaltonen, Lauri A and Renkonen-Sinisalo, Laura and Mecklin, Jukka-Pekka and Matsuda, Koichi and Nakamura, Yusuke and Okada, Yukinori and Gallinger, Steven and Duggan, David J and Conti, David and Newcomb, Polly and Hopper, John and Jenkins, Mark A and Schumacher, Fredrick and Casey, Graham and Easton, Douglas and Shah, Mitul and Pharoah, Paul and Lindblom, Annika and Liu, Tao and Edler, David and Lenander, Claes and Dalén, Johan and Hjern, Fredrik and Lundqvist, Nils and Lindforss, Ulrik and Påhlman, Lars and Smedh, Kennet and Törnqvist, Anders and Holm, Jörn and Janson, Martin and Andersson, Magnus and Ekelund, Susanne and Olsson, Louise and Smith, Christopher G and West, Hannah and ... and Colorectal Tumour Gene Identificat and Coin Collaborative Grp and Swedish Low-Risk Colorectal Canc and COIN Collaborative Group and Swedish Low-Risk Colorectal Cancer Study Group and Colorectal Tumour Gene Identification (CORGI) Consortium and The Swedish Low-Risk Colorectal Cancer Study Group and The COIN Collaborative Group and The Colorectal Tumour Gene Identification (CORGI) Consortium and Inst för molekylär medicin och kirurgi and Karolinska Institutet and Dept of Molecular Medicine and Surgery
Nature Genetics, ISSN 1061-4036, 07/2012, Volume 44, Issue 7, pp. 770 - 776
Journal Article